Pricing &amp; Reimbursement

Renal Cell Cancer Pricing, Reimbursement, and Access

There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.

August 22, 2018

Chronic Heart Failure Pricing, Reimbursement, and Access

Payers were originally extremely worried about the potential cost burden of Entresto, however, the level of concern surrounding the drug is currently moderate as physician uptake has been lower than expected.

April 13, 2018

Crohn’s Disease and Ulcerative Colitis Pricing, Reimbursement, and Access

Payers view spending on inflammatory bowel disease (IBD) drugs as significant, as there is a large patient base requiring expensive biologic therapies. The market has been long dominated by the TNF-alpha inhibitors Humira and Remicade, but more recent biologic launches such as Entyvio and Stelara have focused on novel mechanisms of action.

March 16, 2018

Ovarian Cancer Pricing, Reimbursement, and Access

Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascular endothelial growth factor inhibitor Avastin, followed by poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza, payers are seeing an uptick in spend for the indication.

March 5, 2018

Latest Trends in Orphan Drug Pricing and Reimbursement

It is now some 35 years since the passage of the first law designed specifically to encourage investment in the discovery and development of rare disease treatments. Activity in the sector has been transformed since then.

February 1, 2018

Orphan Drug Access and Pricing in Emerging Markets

This analysis covers the four major emerging regions of the Middle East and Africa, Latin America, Eastern Europe, and Asia-Pacific. Within these regions, relatively wealthier markets with a proven marketplace for orphan medicines have been prioritized.

January 12, 2018

Acute Myeloid Leukemia Pricing, Reimbursement, and Access

The level of concern surrounding the budget impact of acute myeloid leukemia (AML) has traditionally been low due to the relatively small size of the population in comparison to solid tumors, the high severity of the disease, and a lack of branded treatment options. As a result, few access controls are utilized for AML therapies. […]

December 15, 2017

Drug Pricing in the US

Drug prices in the US have been the subject of intense debate over the past 2–3 years, following a surge in spending on prescription medicines and steep price increases in some categories

July 5, 2017

NOACs Pricing, Reimbursement, and Access

A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers.

May 10, 2017

Hemophilia Pricing, Reimbursement, and Access

Over the last two decades, clinical care of hemophilia has improved significantly, extending the life expectancy for this patient population closer to that of the general population. The emergence of virally inactivated plasma-derived clotting factors and then of recombinant clotting factor replacement therapy in the 1980s has revolutionized care for these patients.

January 18, 2017

India Pricing and Reimbursement

Affordability of healthcare is a serious challenge for the majority of the population in India. The lack of properly funded and effective public health services drives a large number of people to receive health services from the private sector.

Turkey Pricing and Reimbursement

To contain overall healthcare expenditure and to rein in the rapid growth of pharmaceutical expenditure, in 2004 Turkey introduced price-setting procedures using an external reference system based on 5–10 reference countries (all from the EU).

Orphan Drug Pricing and Reimbursement

Orphan drugs account for a growing portion of payers’ budgets – and comprise some of the most expensive treatments available.

Japan Pricing and Reimbursement

Pricing and reimbursement processes are closely connected in Japan, with drug pricing largely dependent on innovation. However, achieving premium pricing is difficult, thereby limiting sales potential.